Lixte Biotechnology Holdings, Inc.

Biotechnology • Healthcare • Pasadena, CA, United States • LIXTW (NGM)

Lixte Biotechnology Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colorectal cancer. The company's LB-100 combined with doxorubicin in advanced soft tissue sarcoma is under Phase 1b portion; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.

631 830 7092 680 East Colorado Boulevard, Pasadena, CA 91101, United States

Stock Performance (90 Days)

Data through Nov 28, 2025

Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Aug Decliners: Why Lixte Biotechnology Holdings Inc. (8640) stock is listed among top recommendations - Insider Buying & Weekly Momentum Stock Picks - moha.gov.vn

moha.gov.vn • Jan 6

Lixte Biotechnology Holdings, Inc. Announces $4.3 Million - GlobeNewswire

GlobeNewswire • Dec 18

Lixte Biotechnology stock falls after $4.3 million direct offering - Investing.com

Investing.com • Dec 22

Lixte Simplifies Capital Structure via Share Exchange Deal - TipRanks

TipRanks • Dec 31

Will Lixte Biotechnology Holdings (NASDAQ:LIXT) Spend Its Cash Wisely? - Yahoo Finance

Yahoo Finance • Nov 19

Other Biotechnology Companies

Vertex Pharmaceuticals Inc. / MA

$118.68B market cap

Regeneron Pharmaceuticals, Inc.

$82.72B market cap

Alnylam Pharmaceuticals, Inc.

Frequently Asked Questions

Has LIXTE BIOTECHNOLOGY HOLDINGS, INC. had layoffs?

No layoff events have been recorded for LIXTE BIOTECHNOLOGY HOLDINGS, INC. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.

How many employees does LIXTE BIOTECHNOLOGY HOLDINGS, INC. have?

LIXTE BIOTECHNOLOGY HOLDINGS, INC. has approximately 2 employees.

What industry is LIXTE BIOTECHNOLOGY HOLDINGS, INC. in?

LIXTE BIOTECHNOLOGY HOLDINGS, INC. operates in the Biotechnology industry, within the Healthcare sector.

Is LIXTE BIOTECHNOLOGY HOLDINGS, INC. a publicly traded company?

Yes, LIXTE BIOTECHNOLOGY HOLDINGS, INC. is publicly traded under the ticker symbol LIXTW on the NGM.

Where is LIXTE BIOTECHNOLOGY HOLDINGS, INC. headquartered?

LIXTE BIOTECHNOLOGY HOLDINGS, INC. is headquartered in Pasadena, CA, United States at 680 East Colorado Boulevard, Pasadena, CA 91101, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.